Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 5, 2013, Pages 894-901

  Cornet, A D ^a,b   Hofstra, J J ^c   Vlaar, A P ^c   Tuinman, P R ^c   Levi, M ^c   Girbes, A R ^a,b   Schultz, M J ^c   Groeneveld, A B ^a,b   Beishuizen, A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ARDS; Coagulopathy; Critically ill; Rh APC

Indexed keywords

ANTITHROMBIN; DROTRECOGIN; PLACEBO; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; HUMAN; INJURY SEVERITY; LUNG DISEASE; LUNG INJURY; LUNG LAVAGE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PULMONARY COAGULOPATHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

BLOOD COAGULATION DISORDERS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; PLACEBOS; PROTEIN C; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84877914709     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12179     Document Type: Article

References (38)

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute Respiratory Distress Syndrome: the Berlin Definition. JAMA 2012; 307: 2526-33.
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353: 1685-93.
3. Wind J, Versteegt J, Twisk J, van Bindels AJ, Spijkstra JJ, Girbes AR, Groeneveld AB. Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: A survey. Respir Med 2007; 101: 2091-8.
4. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 2006; 21: 119-43.
5. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia-a review. Crit Care Med 2006; 34: 871-7.
6. Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Meijers JC, Lachmann B. Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med 2005; 31: 724-32.
7. Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Wolthuis EK, Meijers JC, Lachmann B. Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. Eur Respir J 2006; 28: 992-8.
8. Glas GJ, van der Sluijs KF, Schultz MJ, Hofstra JJ, van der Poll T, Levi M. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemost 2013; 11: 17-25.
9. van der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171: 1125-8.
10. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285: L514-21.
11. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35: 1821-8.
12. Bernard GR, Vincent JL, Laterre PF, La Rosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
13. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-64.
14. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952-61.
15. Sebag SC, Bastarache JA, Ware LB. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol 2011; 12: 1481-96.
16. Ware LB, Camerer E, Welty-Wolf K, Schultz MJ, Matthay MA. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291: L307-11.
17. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-24.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
19. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957-63.
20. Vincent JL, Moreno R, Takala J, Willatts S, de Mendonca MA, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707-10.
21. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 720-3.
22. Tuinman PR, Vlaar AP, Cornet AD, Hofstra JJ, Levi M, Meijers JC, Beishuizen A, Schultz MJ, Groeneveld AJ, Juffermans NP. Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Crit Care 2011; 15: R59.
23. Levi M, de Boer JP, Roem D, ten Cate JW, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992; 67: 111-16.
24. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbrück B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-62.
25. Cornet AD, van Nieuw Amerongen GP, Beishuizen A, Schultz MJ, Girbes AR, Groeneveld AB. Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Drug Discov 2009; 4: 219-27.
26. Shua F, Kobayashia H, Fukudomeb K, Tsuneyoshib N, Kimotob M, Teraoa T. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett 2000; 477: 208-12.
27. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
28. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-72.
29. Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G III, Small DS. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72: 391-402.
30. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik HC. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86: 543-9.
31. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
32. Choi G, Schultz MJ, van Till JW, Bresser P, van der Zee JS, Boermeester MA, Levi M, van der Poll T. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24: 786-9.
33. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, van der Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-5.
34. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russel JA, Freebairn JA, Spapen HD, Riess H, Basson B, Johnson G III, Kinasewitz GT. Drotrecogin alfa (activated)(recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642-53.
35. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-8.
36. Kalil AC, Coyle SM, Um JY, La Rosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004; 21: 222-9.
37. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chessnut MS, Philips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178: 618-23.
38. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 2012; 12: 678-86.